Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
General Internal Medicine, University Hospitals, Geneva, Switzerland.
Brivudin is licensed in several European countries for the treatment of herpetic infections, and is considered safe (approximately 1% of patients with transient elevation of liver enzymes) in large multicenter trials.
We report a case of acute brivudin hepatitis documented with a liver biopsy in detail.
Liver biopsy demonstrated acute liver injury with a predominant cytolytic pattern and features suggestive of a drug-induced immunoallergic hepatitis. Elevated ALT levels returned to normal within weeks.
This is the first published case of acute immunoallergic hepatitis due to brivudin.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on